Medpace Holdings, Inc. Q2 2026 earnings report shows revenue of $690.2M, up 13.6% YoY, with oncology bookings driving growth and cancellations decreasing significantly.
Medpace Holdings, Inc. reported Q2 2026 revenue of $690.2 million, reflecting a 13.6% increase year-over-year and beating the consensus estimate of $670 million. This growth was primarily driven by a strong performance in oncology bookings, which represented over half of overall bookings this quarter.
Key Takeaways
- Revenue reached $690.2 million, up 13.6% YoY and above the $670 million consensus estimate.
- Oncology bookings constituted over 50% of total bookings, indicating a shift back towards historical averages after a concentration in metabolic programs.
- Cancellations decreased significantly, contributing to a more favorable net bookings environment compared to previous quarters.
- 2026 guidance for total revenue was updated to a range of $2.805 billion to $2.885 billion, reflecting growth of 10.9% to 14% over 2025.
- Earnings per share guidance for 2026 was set between $17.25 and $17.95, with net income expected to range from $494 million to $514 million.
Strong Revenue Growth Driven by Oncology
Medpace's revenue rose 13.6% year-over-year to $690.2 million, with a sequential increase from $655 million in Q1 2026. This growth was largely fueled by a resurgence in oncology, which accounted for more than half of total bookings in the quarter. The company noted a transition away from the previously dominant metabolic programs, indicating a potential normalization of its revenue mix.
| Metric | Q2 2026 | YoY | QoQ |
|---|---|---|---|
| Revenue | $690.2M | +13.6% | +5.8% |
| Total Bookings | $800M | +12.5% | N/A |
| Cancellations | $50M | -40% | N/A |
Shift in Booking Dynamics
During the call, management highlighted a notable increase in oncology-related bookings, which have returned to being a significant contributor to revenue. The company's backlog conversion rate is anticipated to normalize as oncology programs tend to have longer durations than metabolic programs. This shift could stabilize future revenue streams as management expects a more diversified mix in the coming quarters.
“The top five growth has been driven quite a bit by oncology. I think oncology will retake its position, moving up a few percent in our mix,” said August Troendle, CEO.
Updated Guidance Reflects Confidence
Medpace updated its guidance for full-year 2026, projecting total revenue between $2.805 billion and $2.885 billion, which reflects a growth rate of 10.9% to 14% over 2025's revenue of $2.53 billion. EBITDA is expected to reach between $618 million and $642 million, also indicating robust growth compared to last year.
Management emphasized that this guidance assumes a full-year effective tax rate of 19% to 19.5% and does not include any additional share repurchases, despite having $527 million remaining under its repurchase authorization program.
Analyst Q&A Highlights
During the Q&A session, analysts focused on the sustainability of the oncology-driven growth and potential risks associated with cancellations. Charles Rhee from TD Cowan inquired about the relationship between the concentration of top clients and revenue growth.
“There are some large programs among that top five that account for a good part of that growth,” Troendle responded, indicating that while large clients play a significant role, the company does not foresee this concentration affecting overall growth negatively.
Analysts expressed concerns regarding the potential for cancellations to impact future bookings. However, management noted that cancellations had dropped significantly in Q2, contributing positively to net bookings. The company also highlighted its strong pipeline of awarded programs, suggesting a favorable outlook for the second half of 2026.
Frequently Asked Questions
Did Medpace Holdings, Inc. Common Stock beat earnings estimates in Q2 2026?
Yes, Medpace reported Q2 2026 earnings of $690.2 million, beating the consensus estimate of $670 million, marking a 13.6% year-over-year increase.
What is Medpace's guidance for 2026 revenue?
Medpace updated its 2026 revenue guidance to a range of $2.805 billion to $2.885 billion, reflecting a growth rate of 10.9% to 14% compared to 2025.
How much of the bookings in Q2 2026 came from oncology?
Oncology bookings represented over 50% of total bookings in Q2 2026, marking a significant return to historical averages after a period of concentration in metabolic programs.
What was the trend in cancellations for Medpace in Q2 2026?
Cancellations in Q2 2026 decreased significantly by 40%, contributing to a more favorable net bookings environment compared to previous quarters.
What is the expected EPS range for Medpace in 2026?
Medpace expects its earnings per share for 2026 to be in the range of $17.25 to $17.95.
The next quarter will be crucial for Medpace as it seeks to maintain momentum in its oncology segment while managing the potential risks associated with client concentration and cancellations.
This analysis is based on public earnings call materials and is not investment advice.
